BWAY Brainsway

BrainsWay to Participate in Two Upcoming Investor Conferences

BrainsWay to Participate in Two Upcoming Investor Conferences

CRESSKILL, N.J. and JERUSALEM, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 6th Annual Israel Conference on Thursday, November 12 at 7:00 AM ET. The Company will also participate in one-on-one investor meetings at the Oppenheimer Fall MedTech Summit held on November 12.

About BrainsWay

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders. To learn more, please visit .

Contacts:

BrainsWay:

Judy Huber

SVP and Chief Financial Officer

Investors:

Bob Yedid

LifeSci Advisors

646-597-6989

EN
02/11/2020

Underlying

BWAYBrainsway

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brainsway

 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Reports National Institutes of Health Grant to Leading U.S. ...

BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder New NIH grant awards $2.5 million over 5 years for mechanistic study BURLINGTON, Mass. and JERUSALEM, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded a new grant – totaling approximately $2.5 million over f...

November 4, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay to Report Third Quarter 2025 Financial Results on November 1...

BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025 BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, November 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the fin...

October 28, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Announces Additional Minority-Stake Investments in Leading U...

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term shareholder value BURLINGTON, Mass. and JERUSALEM, Oct. 27, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into two additional minority stake strategic investments, including an equity financ...

October 27, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for...

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD) Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response and remission The accelerated protocol is now commercially available in the United States, expanding patient and provider access BURLINGTON, Mass. and JERUSALEM, Sept. 16, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neuros...

September 16, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Targets Expansion of its Total Addressable Market through a ...

BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd. This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv™Rx device is pending Premarket Approval from the U.S. FDA, and if granted, will become the first FDA-cleared medical device for MDD treatment that can be delivered outside of the clinic BURLINGTON, Mass. and JERUSALEM, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BrainsWa...

August 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch